Fatal hepatic and renal toxicity as a complication of trabectedin therapy for radiation-induced sarcoma.
Trabectedin therapy was prescribed for a patient with radiation-induced sarcoma. Two doses of trabectedin were given before therapy was discontinued with the patient experiencing renal and liver failure. Despite discontinuing trabectedin the patient continued to experience increases in liver transaminases, bilirubin, blood urea nitrogen, and serum creatinine. Hemodialysis was initiated with no improvement. With all other causes being ruled out, trabectedin likely caused hepatic and renal failure leading to death in this patient. Recent literature suggests that patients may benefit from prophylactic dexamethasone as a means of reducing hepatic toxicity.
Pick
Amy M
AM
Department of Pharmacy Practice, School of Pharmacy and Health Professions, Creighton University, 2500 California Plaza, Omaha, NE 68132, USA. apick@creighton.edu
Nystrom
Kelly K
KK
D058186:Acute Kidney Injury / Q000139:chemically induced*; D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects* / Q000627:therapeutic use; D056486:Chemical and Drug Induced Liver Injury; D004149:Dioxoles / Q000009:adverse effects* / Q000627:therapeutic use; D017809:Fatal Outcome; D006801:Humans; D017114:Liver Failure, Acute / Q000139:chemically induced*; D008297:Male; D009381:Neoplasms, Radiation-Induced / Q000188:drug therapy*; D012509:Sarcoma / Q000188:drug therapy*; D019292:Skull Base Neoplasms / Q000188:drug therapy; D044005:Tetrahydroisoquinolines / Q000009:adverse effects* / Q000627:therapeutic use; D000077606:Trabectedin
D018906:Antineoplastic Agents, Alkylating; D004149:Dioxoles; D044005:Tetrahydroisoquinolines; D000077606:Trabectedin